{"title":"表皮生长因子受体突变的非小细胞肺癌肿瘤微环境的全球研究趋势:2014-2023年文献计量分析。","authors":"Xiaoyan Chang, Chenghao Wang, Fei Wang, Linyou Zhang","doi":"10.3389/fimmu.2025.1555216","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy.</p><p><strong>Materials and methods: </strong>We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed.</p><p><strong>Results: </strong>227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and <i>Frontiers in Oncology</i> published most papers (n=16, 14.3%). A total of 7964 co-cited references are related to TME in NSCLC with EGFR mutation. \"EGFR\" is the keyword with the highest centrality (C=0.31) and first appeared. The keywords that burst in the last 1 year (2022-2023) are \"immunotherapy\", \"mechanism\", \"lung neoplasms\", \"T cells\", and \"multicenter\".</p><p><strong>Conclusion: </strong>Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.</p>","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1555216"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965360/pdf/","citationCount":"0","resultStr":"{\"title\":\"Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.\",\"authors\":\"Xiaoyan Chang, Chenghao Wang, Fei Wang, Linyou Zhang\",\"doi\":\"10.3389/fimmu.2025.1555216\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy.</p><p><strong>Materials and methods: </strong>We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed.</p><p><strong>Results: </strong>227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and <i>Frontiers in Oncology</i> published most papers (n=16, 14.3%). A total of 7964 co-cited references are related to TME in NSCLC with EGFR mutation. \\\"EGFR\\\" is the keyword with the highest centrality (C=0.31) and first appeared. The keywords that burst in the last 1 year (2022-2023) are \\\"immunotherapy\\\", \\\"mechanism\\\", \\\"lung neoplasms\\\", \\\"T cells\\\", and \\\"multicenter\\\".</p><p><strong>Conclusion: </strong>Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.</p>\",\"PeriodicalId\":12622,\"journal\":{\"name\":\"Frontiers in Immunology\",\"volume\":\"16 \",\"pages\":\"1555216\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-03-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965360/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Immunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fimmu.2025.1555216\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1555216","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的:非小细胞肺癌(NSCLC)是最常见的肺癌类型,大约一半的患者存在表皮生长因子受体(EGFR)基因突变。EGFR突变后肿瘤微环境的变化与肿瘤的进展和治疗效果密切相关。材料与方法:我们检索Web of Science Core Collection数据库,选择与表皮生长因子受体突变的非小细胞肺癌肿瘤微环境相关的文章。对国家/地区、研究所、作者、期刊、参考文献和关键词进行可视化分析。结果:从WoSCC中获得227项相关研究。这些文章来自102个国家和1179个机构。经网络分析发现,美国与中国的合作强度最大(LS=13),其次是与韩国(LS=3)和与日本(LS=3)。共有2267位作者参与了全部227篇文章。共覆盖112种期刊,其中发表论文最多的期刊是Frontiers in Oncology (n=16, 14.3%)。共有7964篇共被引文献与EGFR突变NSCLC的TME相关。“EGFR”是中心性最高、最先出现的关键词(C=0.31)。最近1年(2022-2023年)爆发的关键词是“免疫治疗”、“机制”、“肺肿瘤”、“T细胞”、“多中心”。结论:一线化疗失败后EGFR突变晚期NSCLC的有效药物治疗是热点之一,其中免疫检查点抑制剂的疗效可能是当前及未来研究需要寻找突破的方向。
Global research trends of tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation: a bibliometric analysis from 2014 to 2023.
Purpose: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and about half of the patients had mutations in the epidermal growth factor receptor (EGFR) gene. Changes in the tumor microenvironment after EGFR mutation are closely related to tumor progression and treatment efficacy.
Materials and methods: We searched the Web of Science Core Collection database to select the articles related to tumor microenvironment in non-small cell lung cancer with epidermal growth factor receptor mutation. The countries/regions, institutes, authors, journals, references, and keywords were visualized and analyzed.
Results: 227 relevant studies were obtained from WoSCC. These articles came from 102 countries and 1179 institutions. After network analysis, it was found that the intensity of USA cooperation with China was the greatest (LS=13), followed by cooperation with South Korea (LS=3) and with Japan (LS=3). A total of 2267 authors participated the all 227 articles. 112 journals were covered, and Frontiers in Oncology published most papers (n=16, 14.3%). A total of 7964 co-cited references are related to TME in NSCLC with EGFR mutation. "EGFR" is the keyword with the highest centrality (C=0.31) and first appeared. The keywords that burst in the last 1 year (2022-2023) are "immunotherapy", "mechanism", "lung neoplasms", "T cells", and "multicenter".
Conclusion: Effective drug treatment of advanced NSCLC with EGFR mutations after failure of first-line chemotherapy is one of the hotspots, in which the efficacy of immune checkpoint inhibitors may be the direction of the current and future studies that need to find a breakthrough.
期刊介绍:
Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.